Rusfertide是每周为多细胞贫血症注射一次的周注射,在第三阶段试验中显示出强有力的成果,减少了对抽血的需求,改善了病人的福利。 Rusfertide, a weekly injectable for polycythemia vera, showed strong results in a Phase 3 trial, reducing need for blood draws and improving patient well-being.

在2025年ASH年会上,Protagonist Therapeutics和Takeda报告说,在VERIFY第3期研究中,rusfertide是治疗多细胞血症的每周注射一次药物,在52周内保持了持续的血红素控制,并减少了瘤手术的需要. At the 2025 ASH Annual Meeting, Protagonist Therapeutics and Takeda reported that rusfertide, a once-weekly injectable therapy for polycythemia vera, maintained durable hematocrit control and reduced phlebotomy needs through 52 weeks in the Phase 3 VERIFY study. 61.9%的患者保持不采血，持续的反应率且无新的安全隐患。 Sixty-one point nine percent of patients remained phlebotomy-free, with sustained response rates and no new safety concerns. 该药物为肝素模拟剂，显示出铁调控和患者报告的结局改善，包括疲劳减轻。 The drug, a hepcidin mimetic, showed improved iron regulation and patient-reported outcomes, including reduced fatigue. 美国食品和药物管理局在2025年8月授予突破性治疗指标,预计在年底之前提交监管文件. FDA breakthrough therapy designation was granted in August 2025, with a regulatory submission expected by year-end.